Duligotuzumab

Drug Profile

Duligotuzumab

Alternative Names: Anti-HER3/EGFR DAF; MEHD-7945A; RG 7597; RO-5541078

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Genentech; Roche
  • Developer Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Discontinued Colorectal cancer; Head and neck cancer

Most Recent Events

  • 30 Jun 2016 Genentech completes a phase I trial for Solid tumours (Combination therapy) in USA and Spain (NCT01986166)
  • 28 Jan 2015 Discontinued - Phase-I for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent) in Belgium (IV)
  • 28 Jan 2015 Discontinued - Phase-I for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top